VitalizeDx partners with the University of Chieti (Italy), a center of excellence for Sport Odontoiatry, to launch ORACARDIO. 

ORACARDIO is the first oral Bio-fingerprinting for Monitoring Athletes Health and Risk of Cardiopathies, particularly Hypertrophic Cardiomyopathy (HCM), a leading cause of sudden death in young competitive athletes worldwide. In this study, we aim to establish a connection between poor oral and dental health, chronic inflammation, and cardiometabolic disease. By providing early differential detection and preventive measures for cardiopathies VitalizeDx supports the overall health and well-being of athletes, boosting their athletic performance.

ORACARDIO aims to expand the diagnostic product portfolio  and companion eubiotic nutraceuticals of VitalizeDx.

We are grateful for the support of MyFitStrip (USA) and BioFusion (Poland) in the realization of this project.

Financing comes from the Eureka and Innosuisse funds.